Portal de Periódicos da CAPES

Cerivastatin-Induced Rhabdomyolysis

2000; American College of Physicians; Volume: 132; Issue: 7 Linguagem: Inglês

10.7326/0003-4819-132-7-200004040-00031

1539-3704

María L. Rodríguez, Carmen Mora, Juan F. Navarro‐González,

Lipoproteins and Cardiovascular Health

Letters4 April 2000Cerivastatin-Induced RhabdomyolysisMaría L. Rodríguez, MD, Carmen Mora, MD, and Juan F. Navarro, MDMaría L. Rodríguez, MDHospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro), Carmen Mora, MDHospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro), and Juan F. Navarro, MDHospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-7-200004040-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Cerivastatin is the last generation of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, the drugs of choice for treating hypercholesterolemia. Tolerability in clinical trials did not differ from that of placebo with regard to serum creatine kinase (CK) levels, and drug-induced myopathy was not reported (1-4). We describe a renal transplant recipient who developed rhabdomyolysis after receiving cerivastatin.In October 1996, a 52-year-old woman with renal failure secondary to polycystic kidney disease had renal transplantation. She was admitted to our hospital in May 1999 for asthenia, myalgia, and muscle weakness. From December 1996 to November 1998 she had ...References1. Stein EA. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Drugs. 1998;56 Suppl 1 25-31. CrossrefMedlineGoogle Scholar2. McClellan KJ, Wiseman LR, McTavish D. Cerivastatin. Drugs. 1998;55:415-20. CrossrefMedlineGoogle Scholar3. Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol. 1998;82 Suppl 4B 40-6. CrossrefGoogle Scholar4. Bischoll H, Heller A. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol. 1998;82 Suppl 4B 18-25. CrossrefGoogle Scholar5. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, et al . Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther. 1999;65:251-61. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced FatalitiesHMG coenzyme-A reductase inhibitorsCardiovascular DrugsPotential role for statins in sickle cell diseaseIn silico prediction of rhabdomyolysis of compounds by self-organizing map and support vector machineIncidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantationLIPID – REGULATING DRUGSSpecial Patient Populations: Transplant RecipientsHMG coenzyme-A reductase inhibitorsPreventing Cardiovascular Outcome in Patients with Renal ImpairmentEffectiveness of Statin-Gemfibrozil Combination Therapy in Patients With Mixed Hyperlipidemia: Experience of a Community Lipid Clinic and Safety Review From the LiteratureIatrogenic and toxic myopathiesRhabdomyolysis Associated with Cerivastatin: Six Cases within 3 Months at One HospitalSevere Rhabdomyolysis and Cerivastatin—Gemfibrozil Combination TherapyRisperidone and severe cerivastatin-induced rhabdomyolysisRabdomiólisis inducida por la combinación de cerivastatina y ciclosporinaDrugs that affect lipid metabolismCerivastatin: Rhabdomyolysis: case reportRhabdomyolysis and HMG-CoA Reductase InhibitorsCERIVASTATIN-INDUCED RHABDOMYOLYSIS IN A RENAL TRANSPLANT ON CYCLOSPORINShort-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trialRhabdomyolysis due to cerivastatin monotherapyRabdomiólisis asociada al tratamiento combinado con cerivastatina y gemfibroziloDIALYTIC TREATMENT OF RHABDOMYOLYSIS-INDUCED ACUTE RENAL FAILURE: OUR EXPERIENCECerivastatin 4 April 2000Volume 132, Issue 7Page: 598KeywordsCreatine kinaseDrug interactionsDrugsLactate dehydrogenaseMetabolic pathwaysMetabolitesMusclesRenal transplantationResearch laboratoriesRhabdomyolysis Issue Published: 4 April 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...